Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics

Alcon (ALC) reported $2.58 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.8%. EPS of $0.76 for the same period compares to $0.74 a year ago.The reported revenue represents a surprise of -1.29% over the Zacks Consensus Estimate of $2.61 billion. With the consensus EPS estimate being $0.71, the EPS surprise was +7.04%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net sales by region- International: $1.42 billion versus $1.45 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change.Net sales by region- United States: $1.16 billion versus the two-analyst average estimate of $1.18 billion. The reported number represents a year-over-year change of +1.7%.Net Sales- Total Surgical: $1.46 billion versus the four-analyst average estimate of $1.48 billion. The reported number represents a year-over-year change of +2.3%.Net Sales- Total Vision care: $1.12 billion versus the four-analyst average estimate of $1.13 billion. The reported number represents a year-over-year change of +6%.Net Sales- Total Surgical- Consumables: $777 million compared to the $786.91 million average estimate based on four analysts. The reported number represents a change of +5.6% year over year.Net Sales- Total Surgical- Equipment/other: $222 million versus $232.7 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.Net Sales- Total Vision Care- Contact lenses: $692 million versus the four-analyst average estimate of $682.51 million. The reported number represents a year-over-year change of +8.8%.Net Sales- Total Vision Care- Ocular health: $430 million versus the four-analyst average estimate of $446.4 million. The reported number represents a year-over-year change of +1.7%.Net Sales- Total Surgical- Implantables: $456 million versus $464.21 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.7% change.Revenues- Other revenues: $19 million versus $17.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +35.7% change.View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned +1.1% over the past month versus the Zacks S&P 500 composite's +2.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks